Abstract
BackgroundChoosing treatments for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients with osimertinib resistance is challenging. We evaluated the safety and efficacy of SNK01 (autologous natural killer...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have